Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
medical crawled date : 2021 - 10 - 04 save search
(Senior) Medical Science Liaison
Published: 2021-10-04 (Crawled : 23:00) - aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.16%
H: 1.62%
C: -1.14%
The (Senior) Medical Science Liaison
Published: 2021-10-04 (Crawled : 23:00) - aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.16%
H: 1.62%
C: -1.14%
The Medical Science Liaison
Published: 2021-10-04 (Crawled : 23:00) - aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.16%
H: 1.62%
C: -1.14%
Medical Science Liaison
Published: 2021-10-04 (Crawled : 23:00) - aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.16%
H: 1.62%
C: -1.14%
Tactile Medical to Release Third Quarter of Fiscal Year 2021 Financial Results on November 8, 2021
Published: 2021-10-04 (Crawled : 22:00) - globenewswire.com
TCMD | $15.04 3.23% 3.12% 410K
|
Health Technology
|
| O: 0.11%
H: 1.36%
C: -7.77%
financial results results
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2021 FINANCIAL RESULTS ON NOVEMBER 11, 2021
Published: 2021-10-04 (Crawled : 21:00) - apyxmedical.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -4.27%
H: 0.0%
C: 0.0%
APYX | $1.495 13.26% 11.71% 190K
|
Health Technology
|
| O: 0.53%
H: 3.65%
C: 2.5%
financial results results
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal FormularyLargest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
AGRX | $0.37 0.0% 95K
|
Health Technology
|
| O: 0.0%
H: 4.04%
C: 0.0%
drug twirla
Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
MDT | $80.38 -1.12% 0.0% 5M
|
Health Technology
|
| O: 0.6%
H: 1.22%
C: -1.54%
stroke risk trial
Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)
Published: 2021-10-04 (Crawled : 05:00) - profoundmedical.com
PROF | News | $7.85 -5.42% -5.73% 17K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: -3.86%
prostate cancer cancer
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.